Heart Rate and Oxygen Saturation Monitoring With a New Wearable Wireless Device in the Intensive Care Unit: Pilot Comparison Trial (Preprint)
BACKGROUND Continuous cardiac monitoring with wireless sensors is an attractive option for early detection of arrhythmia and conduction disturbances and the prevention of adverse events leading to patient deterioration. We present a new sensor design (SmartCardia), a wearable wireless biosensor patch, for continuous cardiac and oxygen saturation (SpO<sub>2</sub>) monitoring. OBJECTIVE This study aimed to test the clinical value of a new wireless sensor device (SmartCardia) and its usefulness in monitoring the heart rate (HR) and SpO<sub>2</sub> of patients. METHODS We performed an observational study and monitored the HR and SpO<sub>2</sub> of patients admitted to the intensive care unit (ICU). We compared the device under test (SmartCardia) with the ICU-grade monitoring system (Dräger-Healthcare). We defined optimal correlation between the gold standard and the wireless system as <10% difference for HR and <4% difference for SpO<sub>2</sub>. Data loss and discrepancy between the two systems were critically analyzed. RESULTS A total of 58 ICU patients (42 men and 16 women), with a mean age of 71 years (SD 11), were included in this study. A total of 13.49 (SD 5.53) hours per patient were recorded. This represents a total recorded period of 782.3 hours. The mean difference between the HR detected by the SmartCardia patch and the ICU monitor was 5.87 (SD 16.01) beats per minute (bias=–5.66, SD 16.09). For SpO<sub>2</sub>, the average difference was 3.54% (SD 3.86; bias=2.9, SD 4.36) for interpretable values. SmartCardia’s patch measures SpO<sub>2</sub> only under low-to-no activity conditions and otherwise does not report a value. Data loss and noninterpretable values of SpO<sub>2</sub> represented 26% (SD 24) of total measurements. CONCLUSIONS The SmartCardia device demonstrated clinically acceptable accuracy for HR and SpO<sub>2</sub> monitoring in ICU patients.